RELMADA THERAPEUTICS, INC. — Form D/A
RELMADA THERAPEUTICS, INC. of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2018-12-10. The offering totals $10.0M, of which $5.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-12-10
- Form: D/A
- Accession: 0001213900-18-017157
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $5.8M
- Remaining: $4.2M
- Minimum investment: $10K
- Investors: 66
- Date of first sale: 2018-10-12
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-324029
Issuer
- Name: RELMADA THERAPEUTICS, INC.
- CIK: 0001553643
- Entity type: Corporation
- Jurisdiction: NEVADA
- Incorporated: 2012
- Address: 880 3RD AVENUE, 12TH FLOOR, NEW YORK, NY, 10022
- Phone: 646 876 3459
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Charles Casamento | Director | SAN FRANCISCO, CA |
| Paul Kelly | Director | Boston, MA |
| Sergio Traversa | Director | Blue Bell, PA |
| Sergio Traversa | Executive Officer | Blue Bell, PA |
| Maged Shenouda | Director | New York, NY |
| Ottavio Vitolo | Executive Officer | New York, NY |
| Chuck Ence | Executive Officer | New York, NY |
| Nabil M Yazgi | Director | NEW YORK, NY |
| Douglas O Beck | Executive Officer | NEW YORK, NY |
| Shreeram O Agharkar | Director | NEW YORK, NY |
| Sandesh O Seth | Director | NEW YORK, NY |
| Eliseo O Salinas | Executive Officer | NEW YORK, NY |
Other filings by this issuer (9)
More